Abstract

estimate the budget impact of incorporating mepolizumab as an add-on alternative versus the best available therapy (BAT) for the treatment of severe eosinophilic asthma (SEA). BAT includes a combined therapy of inhaled corticosteroid and long acting beta agonist, plus short acting beta agonist and oral corticosteroid SOS.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.